50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Acute Myeloid Leukemia - Therapy, Excluding Transplantation Poster III

Monday, December 8, 2008: 5:30 PM-7:30 PM

Hall A (Moscone Center)

Outcome of First Salvage Therapy in Core Binding Factor Associated Acute Myelogenous Leukemia Is Less Than Optimal

Carmen Fava, MD¹^*, Deborah Blamble, PHDP²^*, Susan O'Brien, M.D.³, Guillermo Garcia-Manero, MD³, Sherry Pierce³^*, Hagop Kantarjian, MD³^* and Gautam Borthakur, MD³

¹Ematologia, Luigi Gonzaga Hospital, Orbassano, Italy
²Pharmacy Clinical Programs, U.T. M.D. Anderson Cancer Center, Houston, TX
³Leukemia, U.T. M.D. Anderson Cancer Center, Houston, TX

2953

A Phase I study using Bortezomib with Weekly Idarubicin for the Treatment of Elderly (>60 YEARS) and Relapsed Patients with Acute Myeloid Leukemia (AML)

Dianna Howard, MD¹, Jane Liesveld, MD²^*, Gordon L. Phillips II, MD³, Monica L. Guzman, PhD² and Craig T. Jordan, PhD⁴

¹University of Kentucky, Lexington, KY
²University of Rochester, Rochester, NY
³Wilmot Cancer Center, University of Rochester, Rochester, NY
⁴Univ. of Rochester Medical Ctr., Rochester, NY

2954

Treg Depletion with Interleukin-2-Diphteriatoxin (IL-2DT) Is Sufficient to Induce Tumor Clearance in Acute Myeloid Leukemia (AML)

Christoph Bucher, MD¹, Johanna Zhou, PhD¹^*, Heidi Mondale, PhD¹^*, Meghan Johnson¹^*, Luna Liu¹^*, Christine Vogtenhuber, PhD¹^*, Chris Lees¹^*, Yoichiro Iwakura, PhD²^*, Daniel A Vallera, PhD³^*, Brenda Weigel, MD, MSc¹ and Bruce R. Blazar, MD¹

¹Pediatrics BMT, University of Minnesota, Minneapolis, MN
²Division of Cell Biology, Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, Tokyo, Japan
³Department of Therapeutic Radiology-Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, MN

2955

Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy

Farhad Ravandi, MBBS¹, Jean-Pierre Issa, MD²^*, Guillermo Garcia-Manero, MD²^*, Susan O'Brien, MD²^*, Sherry Pierce, BSN²^*, Jenny Shan, PhD²^*, Srdan Verstovsek, MD, PhD²^*, Stefan Faderl, MD²^*, Jorge Cortes, MD²^* and Hagop Kantarjian, MD²^*

¹Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
²Leukemia, University of Texas - M D Anderson Cancer Center, Houston, TX

2956

A Phase 1 and Correlative Biological Study of CSL360 (anti-CD123 mAb) in AML

Andrew W. Roberts, MBBS, PhD¹, Simon He, MBBS²^*, Kenneth F Bradstock, MB, PhD, FRACP, FRCPA³, Mark S Hertzberg, MBBS, FRACP, FRCP, PhD³^*, Simon T S Durrant, MRCS, MBBS, MRCP, FRCP⁴^*, David Ritchie, MBChB, FRACP, FRCPA, PhD⁵^*, Ian D. Lewis, MBBS, PhD, FRACP, FRCPA⁶, Paula Marlton, MBBS, FRACP, FRCPA⁷, Andrew J McLachlan, PhD⁸^*, Trina M Yeadon, PhD⁹^*, Samantha J Busfield, PhD¹⁰^*, Megan J Barnden, PhD¹⁰^*, Roslyn Davis, BSc, (Hons)¹⁰^*, Sarah Hosback, PhD¹⁰^*, Danijela Mirosa, PhD¹⁰^*, Mark Biondo, PhD¹⁰^*, Simone Bamford, MBBS, FRACGP¹⁰^*, Mark DeWitte, VMD¹⁰^* and Russell Basser, MBBS, MD, FRACP¹⁰

¹Div. of Cancer and Haem., The Walter & Eliza Hall Inst. of Med. Rsch., Parkville, VIC, Australia
²Clinical Haematology and BMT, Royal Melbourne Hospital, Parkville, Australia
³Department of Haematology, Westmead Hospital, Sydney, NSW 2145, Australia
⁴Haematology/BMT Oncology, Royal Brisbane and Womens Hospital, Brisbane, Australia
⁵Dept. of Hematology, Peter MacCallum Cancer Center, Melbourne, Australia
⁶Division of Haematology, I.M.V.S., Adelaide, Australia
⁷Princess Alexandra Hospital, Brisbane, Australia
⁸University of Sydney, Sydney, Australia
⁹Queensland Institute of Medical Research, Herston, Australia
¹⁰CSL Ltd, Parkville, Australia

2957

Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age≥60) with Previously Untreated Acute Myeloid Leukemia (AML)

William Blum, MD, Rebecca Klisovic, MD^*, Shujun Liu, PhD^*, Ramiro Garzon, MD, Cheryl Kefauver, RN^*, Zhongfa Liu, PhD^*, Jon Mickle, CNP^*, Hollie Devine, CNP^*, Steve Devine, MD^*, Michael R Grever, MD^*, Kenneth K Chan, PhD^*, Miguel Villalona-Calero, MD^*, John C. Byrd, MD and Guido Marcucci, MD^*

The Ohio State University, Columbus, OH

2958

Treatment of Relapsed Acute Promyelocytic Leukemia with Oral Arsenic Trioxide: An Eleven-Year Experience

Wing-Yan Au, MD¹^*, Sidney Tam, MD²^*, Anskar Y.H. Leung, MD³^*, Eric Tse, MD³^*, Cyrus Kumana, MD³^* and Yok Lam Kwong, MD³

¹Department of Medicine, Queen Mary Hospital, Hong Kong, China
²Department of Clinical Biochemistry, Queen Mary Hospital, Hong Kong, China
³Department of Medicine, University of Hong Kong, Hong Kong, China

2959

Oral Arsenic Trioxide without Chemotherapy as Maintenance Therapy for Patients with Acute Promyelocytic Leukemia in First Complete Remssion

Wing-Yan Au, MD¹^*, Sidney Tam, MD²^*, Anskar Y.H. Leung, MD³^*, Eric Tse, MD³^*, Cyrus Kumana, MD⁴^* and Yok Lam Kwong, MD³

2960

A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Cloretazine®) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial

Robert Hills, MA, MSc, DPhil¹, Susan O'Brien, M.D.², Verena Karsten, PhD³, Francis Giles, MD⁴ and Alan K. Burnett, MD, FRCP⁵

¹Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
²Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
³Clinical Affairs, Vion Pharmaceuticals, New Haven, CT
⁴The Institute for Drug Development, CTRC, University of Texas Health Science Center, San Antonio, TX
⁵Dept. of Haematology, School of Medicine, Cardiff Univ., Cardiff, United Kingdom

2961

A Randomized Trial Comparing Individualized Vs. Non-Individualized Treatment for Elderly Acute Myeloid Leukemia: JALSG GML200 Study

Atsushi Wakita, MD¹^*, Shigeki Ohtake, MD², Satoru Takada, MD², Fumiharu Yagasaki, MD²^*, Hirokazu Komatsu, MD²^*, Yasushi Miyazaki, MD², Koumei Kubo, MD²^*, Yukihiko Kimura, MD²^*, Akihiro Takeshita, MD², Yoko Adachi, MD²^*, Hitoshi Kiyoi, MD², Takuhiro Yamaguchi, PhD²^*, Minoru Yoshida, MD²^*, Kazunori Ohnishi, MD²^*, Shuichi Miyawaki, MD², Tomoki Naoe, MD², Ryuzo Ueda, MD² and Ryuzo Ohno, MD²^*

¹Department of Hematology and Oncology, Higashi Municipal Hospital of Nagoya, Nagoya, Japan
²Japan Adult Leukemia Study Group (JALSG), Japan

2962

Low Dose Ara-C Versus Low Dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 “Pick a Winner” Comparison

Alan K. Burnett, MD, FRCP¹, Robert Hills, MA, MSc, DPhil², Donald Milligan, MD, MBChB³, William J. Kell, MD, MB⁴, Keith Wheatley, DPhil⁵, Andres E. Virchis, FRCP, FRCPath⁶ and Nigel H. Russell, MD⁷

¹Dept. of Haematology, School of Medicine, Cardiff Univ., Cardiff, United Kingdom
²Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
³Dept. of Hematology, Birmingham Heartlands Hospital, Birmingham, ARRAY(0xc1edb84)
⁴Dept. of Haematology, University Hospital of Wales, Cardiff, United Kingdom
⁵Division of Medical Sciences, Robert Aitken Institute, Birmingham, ARRAY(0xc0fada0)
⁶Dept. of Hematology, Barnet Hospital, Barnet, ARRAY(0xc0e2b60)
⁷Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, ARRAY(0xc1c3fa4)

2963

Phase I, Dose-Escalation Study of 2 Dosing Regimens of AS703569, An Inhibitor of Aurora and Other Kinases, Administered Orally in Patients with Advanced Hematological Malignancies

Anne Sonet¹^*, Carlos Graux¹^*, Johan Maertens²^*, Christine-Maria Hartog³^*, Justus Duyster⁴^*, Katharina G�tze⁴^*, Jochen Greiner⁵^*, Marie-Luise H�tter⁵^*, Alois Gratwohl⁶, Dominik Heim⁶, Dagmar Hess⁷^*, Yves Chalandon⁸, Athos Gianella-Borradori⁹, Narmyn Rejeb⁹^* and Oliver Ottmann³

¹UCL Mont-Godinne, Yvoir, Belgium
²University Hospital Gasthuisberg, Leuven, Belgium
³Goethe University, Frankfurt, Germany
⁴Technical University of Munich, Munich, Germany
⁵University of Ulm, Ulm, Germany
⁶University Hospital Basel, Basel, Switzerland
⁷Kantonsspital, St. Gallen, Switzerland
⁸University Hospital Geneva, Geneva, Switzerland
⁹Merck Serono, Geneva, Switzerland

2964

Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia

Pamela S. Becker, MD, PhD¹, Elihu Estey, MD²^*, Stephen Petersdorf, MD³, Paul C. Hendrie, MD, PhD⁴, John M. Pagel, MD, PhD², Derek Stirewalt, MD⁵, Andrei Shustov, MD¹, Barry E. Storer, PhD⁶^* and Frederick R. Appelbaum, MD⁷

¹University of Washington, Seattle, WA
²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
³Seattle Cancer Care Alliance, Seattle, WA
⁴Univ. of Washington Med. Ctr., Seattle, WA
⁵Fred Hutchinson Cancer Research Ctr., Seattle, WA
⁶Fred Hutchinson Cancer Research Center/ University of Washington, Seattle, WA
⁷Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA

2965

Continued Treatment with An Outpatient Maintenance Schedule of Decitabine in Older AML Patients Ineligible for Induction Chemotherapy: Results of the 00331 Phase II Multicenter Trial

Michael L�bbert¹^*, Mathias Schmid²^*, Bj�rn R�ter³^*, Ulrich Germing⁴^*, Volker Rethwisch⁵^*, Arnold Ganser⁶, Uwe Platzbecker⁷, Oliver Galm⁸^*, Wolfram Brugger⁹^*, Pierre W Wijermans¹⁰, Claudia Schmoor¹¹^* and Hartmut D�hner¹²

¹Dept. of Hematology/Oncology, University Medical Center, Freiburg, Germany
²University Hospital Ulm, Germany
³Dept. Hematology/Oncology, University Medical Center, Freiburg, Germany
⁴University Hospital D�sseldorf, Dusseldorf, Germany
⁵Catholic Hospital, Hagen, Germany
⁶Hannover Medical School, Hannover, Germany
⁷University Hospital Dresden, Germany
⁸University Hospital Aachen, Aachen, Germany
⁹Hospital Villingen-Schwenningen, Germany
¹⁰Hospital Leyenburg, The Hague, Netherlands
¹¹Center for Clinical Trials, University Medical Center, Freiburg, Germany
¹²University of Ulm, Germany

2966

Ten Year Follow up Analysis of the OSHO Phase III Trial (AML 96) Comparing Different Application Modes of AraC in Patients below 60 Years with Acute Myeloid Leukemia (AML): No Impact of AraC-Application Mode on Remission Rate, Toxicity, Disease-Free Survival or Overall Survival

Cornelia Becker¹^*, Rainer Krahl¹^*, Antje Schulze²^*, Georg Maschmeyer²^*, Christian Junghan�²^*, Astrid Franke²^*, Norma Peter²^*, Mathias Haenel²^*, Ulrich Wedding²^*, Hans-Heinrich Wolf²^*, Detlev Haehling²^*, Johannes Meran²^*, Gottfried Doelken²^*, Dietrich Kaempfe²^*, Erika Kettner²^*, Norbert Grobe²^*, Axel Florschuetz²^*, Ute Kreibich²^*, Veronika Schirmer²^*, Thomas Ittel²^*, Mathias Schulze²^*, Renate Huhn²^*, Ernst Zschuppe²^*, Bernd Opitz²^*, Michael Assmann²^*, Dirk Hasenclever²^*, Wolfram Poenisch¹^*, Werner Helbig¹^* and Dietger W. Niederwieser, MD³

¹Internal Medicine, Hematology and Oncology, University of Leipzig, East German Hematology and Oncology Study Group (OSHO), Leipzig, Germany
²East German Hematology and Oncology Study Group (OSHO), Leipzig, Germany
³Abteilung Hamatologie/Onkologie, Universitat Leipzig, Leipzig, Germany

2967

A Phase I Dose Escalation Study of KW-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed / Refractory AML, ALL and MDS or Resistant / Intolerant CML

Jorge Cortes, MD¹, Gail J. Roboz, MD², Hagop M. Kantarjian¹^*, Eric J. Feldman, MD³, Judith E. Karp, MD⁴, Keith W. Pratz, MD⁵, Niranjan S. Rao, PhD⁶^*, Shiro Akinaga, PhD⁷^* and Mark J. Levis, MD, PhD⁸

¹M.D. Anderson Cancer Center, Houston, TX
²Medicine, Weill Cornell Medical College, New York, NY
³Cornell Med. Ctr., New York-Presbyterian Hosp., New York, NY
⁴Oncology, Johns Hopkins Hospital, Baltimore, MD
⁵Hematology, Sidney Kimmel Comprehensive Cancer Center at JHU, Baltimore, MD
⁶Clinical Pharmcology, Kyowa Pharmaceutical, Inc., Princeton, NJ
⁷Oncology, Kyowa Hakko Kirin Co Ltd, Tokyo, Japan
⁸Johns Hopkins University, Baltimore, MD

2968

Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML

Steven L Allen¹, Harry P Erba²^*, David A. Rizzieri³, Margaret O'Donnell⁴^*, Bayard Powell⁵, Ante S Lundberg⁶^*, John M Bennett⁷^* and Robert L Capizzi⁶^*

¹North Shore University Hospital, Manhasset, NY
²University of Michigan Medical School, Ann Arbor, MI
³Duke University Medical Center, Durham, NC
⁴City of Hope National Medical Center, Duarte, CA
⁵Wake Forest University Medical Center, Winston Salem, NC
⁶Antisoma Research Ltd, Cambridge, MA
⁷University of Rochester Medical Center, Rochester, NY

2969

In-Vitro Culture of Human CD80/IL2 Lentivirus Transduced Acute Myeloid Leukemia Cells (AML) Promote NK Cell Activation and Cytolytic Activity

Wendy Ingram^*, Lucas Chan^*, Hayrettin Guven^*, Shahram Kordasti^*, Linda Barber^*, Nicola Hardwick^*, David Darling^*, Ghulam J Mufti and Farzin Farzaneh^*

Department of Haematological Medicine, King's College London, London, United Kingdom

2970

Front-Line Therapy with Arsenic Trioxide/All-Trans-Retinoic Acid Combination and Chemotherapy Improves Cure Rates in Newly Diagnosed Patients with Acute Promyelocytic Leukemia

Jiong Hu, MD¹, Yuan-fang Liu¹^*, Chuan-feng Wu¹^*, Guang-biao Zhou²^*, Zhi-Xiang Shen¹^*, Jun-min Li¹^*, Zhen-Yi Wang¹^*, Sai-Juan Chen¹^* and Zhu Chen¹^*

¹Dept. of Hematology, Shanghai Institute of Hematology, RuiJin Hospital, Shanghai, China
²Guangzhou Institute of Biomedicine and Health,Chinese Academy of Sciences(GIBH), Guangzhou, China

2971

Hematological Improvement in AML/RAEB Elderly Patients Treated with Valproic Acid and Low-Dose ARA-C

Maria Teresa Corsetti, MD¹^*, Flavia Salvi, MD¹^*, Sonia Perticone¹^*, Bernardino Allione, MD¹^*, Anna Baraldi, MD¹^*, Alessandro Bellora, MD¹^*, Lorella De Paoli, MD¹^*, Simona Gatto, MD¹^*, Daniela Pietrasanta, MD¹^*, Valeria Primon, MD¹^*, Massimo Pini, MD¹^*, Anna Tonso, MD²^*, Marco Musi, MD³^*, Giorgio Ciravegna, MD⁴^*, Francesco Zallio, MD⁴^* and Alessandro Levis, MD¹

¹Hematology, Ospedale Civile, Alessandria, Italy
²Medicine, Osp.Infermi, Biella, Italy
³Oncology, Az USL, Aosta, Italy
⁴Oncology, Ospedale C.Massaia, Asti, Italy

2972

Mito-FLAG with Ara-C as Bolus Vs. Continuous Infusion in Recurrent AML – Results of a Prospective Randomized Intergroup Study of the East German Study Group Hematology / Oncology (OSHO) and the Study Alliance Leukemias (SAL)

Mathias Hanel¹, Kai Friedrichsen¹^*, Frank Kroschinsky²^*, Wolfram Poenisch³^*, Kerstin Schaefer-Eckart⁴^*, Walter Aulitzky⁵, Norma Peter⁶^*, Sascha Neugebauer⁷^*, Regina Herbst¹^*, Annette Hanel¹^*, Martin Wilhelm⁴, Dietger Niederwieser³, Gerhard Ehninger² and Friedrich Fiedler¹^*

¹Clinic of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany
²Medical Clinic I, University Hospital, Dresden, Germany
³Department of Hematology/Oncology, University of Leipzig, Leipzig, Germany
⁴Medical Clinic 5, Klinikum Nuernberg, Nuernberg, Germany
⁵Medical Center, Robert-Bosch-Hospital, Stuttgart, Germany
⁶Medical Clinic II, Carl-Thiem-Klinikum, Cottbus, Germany
⁷WiSP GmbH, Langenfeld, Germany

2973

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

C. M�ller-Tidow, MD¹^*, Gesine Bug, MD²^*, Richard Schlenk, MD³, Michael L�bbert, MD, PhD⁴^*, Alwin Kr�mer, MD⁵^*, Juergen Krauter, MD⁶^*, David Nachbaur, MD⁷^*, Peter Valent, MD⁸, Tillmann Taube, MD⁹^*, Gerd Munzert, MD⁹^*, Kang-Hun Lee, MD⁹^* and Hartmut Dohner, MD³

¹University Hospital, M�nster, Germany
²Hematology/Oncology, University Hospital, Frankfurt, Germany
³Internal Medicine III, University of Ulm, Ulm, Germany
⁴University of Freiburg Medical Center, Freiburg, Germany
⁵Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (dkfz), Heidelberg, Germany
⁶Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
⁷Internal Medicine V, Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria
⁸Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
⁹Clinical Research Oncology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/Riss, Germany

2974

Poly ADP Ribose Polymerase (PARP) Inhibitors Induce Apoptosis Alone or Synergistically with Histone Deacetylase Inhibitors in Primary Acute Myeloid Leukemic Patient Cells

Terry J Gaymes, DPhil¹^*, Sydney Shall, Dphil¹^*, Farzin Farzaneh, DPhil²^* and Ghulam J Mufti, MBBS, DM, FRCP, FRCPath³

¹Haematological Medicine, Kings College London, London, United Kingdom
²Haematological Medicine, King's College London, London, United Kingdom
³Department of Haematological Medicine, Kings College London, London, United Kingdom

2975

Final Report of “Korean Multicenter AML-2000 Trial”: Intention to Treat Analysis Based on Cytogenetics Risk

Yeung-Chul Mun¹, Jae Hoon Lee², Byoung Kook Kim³, Seonyang Park³^*, Sung-Soo Yoon³, Soo-Mee Bang³, Hyung Nam Moon⁴^*, Deog-Yeon Jo⁵^*, Chul Soo Kim⁶, Doyeon Oh⁷^*, Jae Hoo Park⁸^*, Young-Don Joo⁹, Dae Young Zang¹⁰^*, Inho Kim³^*, Eun Kyoung Cho²^*, Se Hoon Park²^*, Jung-Hye Choi¹¹^*, Jong Jin Seo⁴^*, Young Joo Min⁸^*, Hawk Kim⁸^*, Moon Hee Lee⁶^*, Won Sik Lee⁹^*, So Young Chong⁷^*, Myung Soo Hyun¹²^*, Kyung Hee Lee¹²^*, Hong Suk Song¹³^*, Heung Sik Kim¹⁴^*, Hyo Jin Kim¹⁵^*, Hyuk Chan Kwon¹⁵^*, Sung Hyun Kim¹⁵^*, Myung Ju Ahn¹⁶^*, Jin Seok Ahn¹⁶^*, Yeon Hee Park¹⁶^*, Kyung Tae Park¹⁷^*, Hun-Mo Ryoo¹⁸, Sung Hwa Bae¹⁸^*, Hwi-Joong Yoon¹⁹, Bong-Seog Kim²⁰^*, Seung-Hyun Nam²⁰^*, Thad. T Ghim²¹^* and Chu-Myong Seong¹

¹Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, South Korea
²Department of Internal Medicine, Gachon Medical School, Incheon
³Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
⁴Department of Pediatrics, University of Ulsan College of Medicine, Ulsan, South Korea
⁵Department of Internal Medicine, Chungnam National University Medical School, Daejeon, South Korea
⁶Department of Internal Medicine, Inha University College of Medicine, Seoul, South Korea
⁷Department of Internal Medicine, Pochon CHA University Collgeg of Medicine
⁸Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan, South Korea
⁹Department of Internal Medicine, Inje University College of Medicine, Busan, South Korea
¹⁰Department of Internal Medicine, Hallym University College of Medicine
¹¹Department of Internal Medicine, Hanyang University College of Medicine, South Korea
¹²Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, South Korea
¹³Department of Internal Medicine, Kyemyung University College of Medicine, Daegu
¹⁴Department of Pediatrics, Kyemyung University College of Medicine, Daegu
¹⁵Department of Internal Medicine, Dong-A University Collgeg of Medicine, Busan
¹⁶Department of Internal Medicine, Sunkyunkwan University School of Medicine, Seoul
¹⁷Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul, South Korea
¹⁸Department of Internal Medicine, Daegu Catholic University School of Medicine, Namgu, South Korea
¹⁹Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, South Korea
²⁰Department of Internal Medicine, Seoul Veterans Hospital, Seoul
²¹Department of Pediatrics, Korea Cancer Center Hospital, Goyang

2976

Prognostic Significance of Time to Relapse in Pediatric AML: Results from the International Randomised Phase III Study Relapsed AML 2001/01

G.J.L. Kaspers¹, M. Zimmermann²^*, D. Reinhardt², B. Gibson³^*, R. Tamminga¹^*, H. Armendariz⁴^*, M. Dworzak⁵^*, S. Ha⁶, L. Hovi⁷^*, A. Maschan⁸^*, A. Baruchel⁹, Y. Bertrand⁹^*, B. Razzouk¹⁰^*, C. Rizzari¹¹^*, P. Smisek¹²^*, O. Smith¹³^*, B. Stark¹⁴ and U. Creutzig²

¹DCOG, The Hague, Netherlands
²BFM-G, Germany
³UK CLWP, United Kingdom
⁴GATLA, Argentina
⁵BFM-A, Austria
⁶Hong Kong
⁷NOPHO
⁸Moscow-Minsk
⁹FRALLE/CLCG, France
¹⁰St. Jude, TN
¹¹University of Milano - Bicocca, Monza, Italy
¹²CPH, Czech Republic
¹³UK CLWP, Ireland
¹⁴Israel

2977

Long-Term Continuing Second Complete Remission (CCR2) despite Allogeneic Stem Cell Transplantation in CR1: Results from the International Randomised Phase III Study Pediatric Relapsed AML 2001/01

2978

The Impact of MN1 Over-Expression on the Outcome of Younger Patients with AML Treated with Intensive Chemotherapy with or without ATRA Therapy

Carol Guy¹^*, Amanda Gilkes¹^*, Rosemary Gale, PhD², David C. Linch, FRCP³, Robert Hills, MA, MSc, DPhil¹ and Alan K. Burnett, MD, FRCP⁴

¹Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
²Haematology, 3rd floor, Cancer Institute, Paul O'Gorman Building, London, United Kingdom
³Department of Hematology, University College London, London, ARRAY(0xc117b58)
⁴Dept. of Haematology, School of Medicine, Cardiff Univ., Cardiff, United Kingdom

2979

Reliability of Leukostasis Grading Score to Identify High Risk Patients with Hyperleukocytic Leukemia

Nicola Piccirillo, MD^*, Luca Laurenti, MD^*, Patrizia Chiusolo, MD^*, Federica Sor�, MD^*, Maria Bianchi, MD^*, Silvia De Matteis, MD^*, Livio Pagano, MD^*, Gina Zini, MD, Giuseppe d'Onofrio, MD^*, Giuseppe Leone, MD and Simona Sica, MD^*

Istituto di Ematologia, Universit� Cattolica del Sacro Cuore, Rome, Italy

2980

Chemokine Induction by All-Trans Retinoic Acid in Acute Promyelocytic Leukemia - Triggering the Retinoic Acid Syndrome

Maaike Luesink, MD¹^*, Jeroen Pennings, PhD¹^*, Willemijn Wissink, Msc¹^*, Peter Linssen¹^*, Petra Muus, MD, PhD², Rolf Pfundt, PhD³^*, Richard Huijbens⁴^*, Theo de Witte, MD, PhD¹^*, Bert van der Reijden, PhD¹ and Joop H. Jansen, PhD¹

¹Central Hematology Laboratory, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
²Department of Hematology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
³Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
⁴Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

2981

Evaluation of Combinational Therapy of MDM2-Antagonist Nutlin-3 and HDAC-Inhibitor Valproic Acid in Acute Myeloid Leukemia in Vitro and in Vivo

Emmet McCormack¹^*, Ingvild Haaland¹^*, Gurid Ven�s¹^*, Rakel Brendsdal Forthun¹^*, �ystein Bruserud²^* and Bj�rn Tore Gjertsen²

¹Institute of medicine, Hematology section, University of Bergen, Bergen, Norway
²Department of internal medicine, Hematology section, Haukeland University Hospital, Bergen, Norway

2982

Phase I/II Study of Tipifarnib and Bortezomib in the Treatment of Poor Risk Adult Acute Myeloid Leukemia

Stefania Paolini¹^*, Emanuela Ottaviani¹^*, Barbara Lama¹^*, Federica Salmi¹^*, Cristina Clissa¹^*, Antonio Curti¹^*, Carlo Finelli¹^*, Panagiota Giannoulia¹^*, Ilaria Iacobucci¹^*, Claudio Laterza¹^*, Cristina Papayannidis¹^*, Sarah Parisi¹^*, Pier Paolo Piccaluga¹, Nicola Vianelli¹^*, Giuseppe Saglio, MD²^*, Renato Fanin³^*, Fortunato Morabito⁴^*, Alfonso Zaccaria⁵^*, Francesco Lauria⁶, Dino Amadori⁷^*, Michele Baccarani¹^* and Giovanni Martinelli¹^*

¹Department of Hematology/Oncology L. and A. Ser�gnoli, University of Bologna, Bologna, Italy
²Department of Clinical and Biological Sciences, University of Turin, Orbassano,Turin, Italy
³Hematology, Udine University, Udine, Italy
⁴O.U. Haematology, Azienda Ospedaliera, Cosenza, Italy
⁵Ematologia-Ravenna, Italy
⁶University of Siena, Department of Hematology and Transplants, Siena, Italy
⁷U.O. Oncologa Medica, IRST- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC), Italy

2983

Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 (²¹³Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML)

Todd Rosenblat, MD, MS¹^*, Michael R. McDevitt, PhD²^*, Deborah A. Mulford, MD¹^*, Neeta Pandit-Taskar, MD³^*, Mark A. Weiss, MD¹, Mark L. Heaney, MD, PhD¹, Suzanne Chanel, RN¹^*, Alfred Morgenstern, PhD⁴^*, Steven M. Larson, MD³^*, David A. Scheinberg, MD, PhD²^* and Joseph G. Jurcic, MD¹

¹Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
²Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY
³Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY
⁴Institute for Transuranium Elements, European Commission Joint Research Center, Karlsruhe, Germany

2984

Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias

Eric J. Feldman, MD¹, Jeffrey Lancet, MD², Jonathan E. Kolitz, MD³, Ellen Ritchie, MD⁴^*, Alan F. List, MD⁵, Ekatherine Asatiani, MD⁶^*, Tania J Curcio¹^*, Michelle Burton, RN²^*, Marge Fricano, BSN³^*, Christine Swenson⁷^*, Lawrence D Mayer, PhD⁸^* and Arthur C. Louie, MD⁷

¹Cornell Med. Ctr., New York-Presbyterian Hosp., New York, NY
²H. Lee Moffitt Cancer Ctr. & Rsrch. Institute, Tampa, FL
³Medicine, North Shore University Hospital, Lake Success, NY
⁴New York Presbyterian, Weill Cornell Medical College, New York, NY
⁵H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁶Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC
⁷Celator Pharmaceuticals, Inc., Princeton, NJ
⁸Celator Pharmaceuticals Inc., Princeton, NJ

2985

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome

Gautam Borthakur, MD¹^*, Zeev Estrov¹^*, Guillermo Garcia-Manero, MD¹, Betsy Williams¹^*, Jay K. Wathen²^*, Marina Konopleva¹^*, Jan Burger¹^*, Alessandra Ferrajoli¹^*, Solly George¹^* and Hagop Kantarjian¹^*

¹Leukemia, U.T. M.D. Anderson Cancer Center, Houston, TX
²Quantitative Sciences Division, U.T. M.D. Anderson Cancer Center, Houston, TX

2986

Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2)

Steven Grant, MD¹, Sarah Kolla¹^*, Leonardo Andres Sirulnik, MD, PhD²^*, Geoffrey Shapiro²^*, Jeffrey Supko²^*, Brenda Cooper³^*, Edward Perkins¹^*, Viswanathan Ramakrishnan¹^*, Igor Espinoza-Delgado, MD⁴^*, M B Tombes¹^* and John D Roberts¹^*

¹Massey Cancer Center, Virginia Commonwealth University, Richmond, VA
²Dana-Farber Cancer Inst., Boston, MA
³Ireland Cancer Center, University Hospitals Case Medical Center, Cleveland, OH
⁴Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

2987

Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy

Farhad Ravandi, MBBS¹, Deepa Sampath, PhD¹^*, William Plunkett, PhD¹^*, Betsy Williams, RN¹^*, Michelle Burton, RN²^*, Srdan Verstovsek¹, Stefan Faderl, MD¹, Guillermo Garcia-Manero, MD¹, Vernon Alvarez, PhD³^*, Michael D Becker³^*, Alan F. List, MD², Said Sebti, PhD²^*, Hagop M. Kantarjian, MD¹ and Jeffrey Lancet, MD²

¹M.D. Anderson Cancer Center, Houston, TX
²H. Lee Moffitt Cancer Ctr. & Rsrch. Institute, Tampa, FL
³VioQuest Pharmaceuticals, Inc., Basking Ridge, NJ

2988

Impact of CRi on the Outcome of Elderly Patients with Untreated Acute Myeloid Leukemia (AML)

Anne Etienne¹^*, Aude Charbonnier¹^*, Thomas Prebet¹^*, Diane Coso¹^*, Evelyne D'Incan¹^*, Marie-Francoise Doglio¹^*, Daniele Sainty²^*, Marie-Joelle Mozziconacci²^*, Jerome Rey¹^* and Norbert Vey¹

¹Hematology, Institut Paoli-Calmettes, Marseille, France
²Biopathologie, Institut Paoli-Calmettes, Marseille, France

2989

Toll-Like Receptor-7 Agonist Directly Inhibits the Growth and Induces Apoptosis of MLL-AF9 Leukemia Cells in Vitro and in Vivo

Xueqing Liang, MD, PhD¹^*, Ashish Kumar, MBBS, PhD², Zhimei Wang, MD²^*, Brenda Weigel, MSc, MD³, Bruce R Blazar, M.D.² and Wei Chen, MD, PhD¹

¹Pediatric Hematology-Oncology/BMT, University of Minnesota, Minneapolis, MN
²Pediatric Heme/Onc/BMT, University of Minnesota, Minneapolis, MN
³University of Minnesota, Minneapolis, MN

2990

Age and Prognosis in Pediatric AML

Pernille Wendtland Edslev¹^*, Jonas Abrahamsson²^*, Niels Clausen¹^*, Erik Forestier³^*, G�ran Gustafsson⁴^*, Jesper Heldrup⁵^*, Liisa Hovi⁶^*, Kirsi Jahnukainen⁷^*, Gudmundur Jonmundsson⁸^*, Josefine Palle⁹^*, Bem Zeller¹⁰^* and Henrik Hasle¹¹

¹Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
²Pediatrics, Queen Silvia Children's Hospital, Gothenburg, Sweden
³Pediatrics, Ume� University Hospital, Ume�, Sweden
⁴Children Cancer Research Unit, Karolinska Hospital, Stockholm, Sweden
⁵Pediatrics, University Hospital, Lund, Lund, Sweden
⁶Pediatrics, University of Helsinki, Helsinki, Finland
⁷Pediatrics, University of Turku, Turku, Finland
⁸Pediatrics, Landspitalinn, Reykjavik, Iceland
⁹Pediatrics, University of Uppsala, Uppsala, Sweden
¹⁰Pediatrics, Rikshospitalet, Oslo, Norway
¹¹Department of Pediatrics, Aarhus University Hospital, Skejby, Aarhus, Denmark

2991

Azacytidine and Gemtuzumab Ozogamicin Co-Operate to Inhibit the Wnt Pathway and Increase Cytotoxicity in AML

Mays Jawad, BSc, PhD¹^*, Nigel H. Russell, MD² and Monica Pallis, PhD³^*

¹Academic Haematology, University of Nottingham, Nottingham, United Kingdom
²Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, ARRAY(0xc1c3fa4)
³Academic Haematology, Nottingham University Hospitals, Nottingham, United Kingdom

2992

Incidence, Outcome and Risk Factors of Pseudotumor Cerebri after All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy in Patients with Acute Promyelocytic Leukemia

Pau Montesinos, MD^*, Edo Vellenga^*, Aleksandra Holowiecka^*, Chelo Rayon^*, Gustavo Milone^*, Javier de la Serna^*, Angel Leon^*, Juan Bergua^*, Concha Rivas^*, Jose Gonzalez^*, Jordi Esteve^* and Miguel A. Sanz, MD, PhD

On behalf of the PETHEMA, HOVON, PALG, and GATLA cooperative groups, Valencia, Spain

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH